Product Type
Fc Silent Antibody
Description
The Fc-mediated effector functions of antibodies include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), and have been shown to be crucial for the therapeutic efficacy of most clinically approved antibodies. However, engaging immune effectors through FcγR and complement interactions may be detrimental to certain mAb mechanisms of action and so Fc-null or -silenced antibodies may be desired.
Creative Biolabs uses site-directed mutagenesis technology to generate Fc-silenced antibody with reduced effector functions. The mutated Fc domains eliminate the binding of Fc receptors (FcγR, FcR), thereby leading to a significant reduction in ADCC and CDC in comparison to WT IgG.
Immunogen
Antibody ZKA25 was isolated from peripheral blood mononuclear cell (PBMC) and blood plasma collected from a ZIKV-infected patient.
Species
Virus
Cross reactivity
Zika
Clonality
Monoclonal
Clone Number
ZKA25
Conjugation
Unconjugated
Buffer
PBS only
Application
EL
Storage Instructions
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Alternative Names
CDKN1A, CAP20, CDKN1, CIP1, MDA-6, P21, SDI1, WAF1, p21CIP1, cyclin-dependent kinase inhibitor 1A, cyclin dependent kinase inhibitor 1A
